Phreesia, Inc. (NYSE:PHR) Director Sells $77,531.34 in Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) Director Lisa Egbuonu-Davis sold 2,802 shares of the stock in a transaction dated Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the completion of the transaction, the director now owns 22,037 shares in the company, valued at approximately $609,763.79. The trade was a 11.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Phreesia Price Performance

Shares of NYSE:PHR traded up $0.50 on Friday, hitting $28.45. The company had a trading volume of 2,170,779 shares, compared to its average volume of 453,404. The business has a 50 day moving average of $25.45 and a 200 day moving average of $26.07. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The company has a market cap of $1.69 billion, a PE ratio of -38.45 and a beta of 0.68. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02.

Phreesia (NYSE:PHR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The company had revenue of $115.94 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the firm posted ($0.05) EPS. Phreesia's revenue was up 14.5% on a year-over-year basis. As a group, equities analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PHR. Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, March 13th. Wall Street Zen upgraded Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. DA Davidson dropped their price target on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. KeyCorp dropped their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Finally, Citigroup restated a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $31.64.

Institutional Investors Weigh In On Phreesia

Several hedge funds have recently modified their holdings of PHR. Johnson Financial Group Inc. increased its stake in Phreesia by 381.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after acquiring an additional 896 shares during the last quarter. Quarry LP increased its stake in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock worth $71,000 after buying an additional 1,923 shares during the last quarter. KBC Group NV acquired a new stake in shares of Phreesia in the 1st quarter valued at about $74,000. Smartleaf Asset Management LLC raised its stake in Phreesia by 154.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company's stock valued at $89,000 after buying an additional 2,090 shares in the last quarter. Finally, CWM LLC raised its position in shares of Phreesia by 994.9% during the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after acquiring an additional 3,671 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.